Lambert F. R. Span

University Medical Center Groningen — Netherlands

Medicine · Health Sciences

27h-index2.2kcitations77works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antifungal resistance and susceptibility(26), Fungal Infections and Studies(14), Mast cells and histamine(13), Acute Myeloid Leukemia Research(9), Eosinophilic Disorders and Syndromes(8)

Publications77 total

Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up
Clinical Lymphoma Myeloma & Leukemia·2024
MPN-274 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up
Clinical Lymphoma Myeloma & Leukemia·2024· 3 cited
Inflammation altered correlation between <i>CYP2C19</i> genotype and <scp>CYP2C19</scp> activity in patients receiving voriconazole
Clinical and Translational Science·2024· 5 citedOpen Access
Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
Blood Advances·2024· 6 citedOpen Access
Hereditary Alpha Tryptasemia: Validation of a Single-Well Multiplex Digital Droplet PCR Assay in a Cohort of Symptomatic Patients
Clinical Chemistry·2023· 4 citedOpen Access
MPN-295 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analyses from the Phase 2 PATHFINDER Study With 2-Year Follow-Up
Clinical Lymphoma Myeloma & Leukemia·2023
POSTER: MPN-295 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analyses from the Phase 2 PATHFINDER Study With 2-Year Follow-Up
Clinical Lymphoma Myeloma & Leukemia·2023
P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP
HemaSphere·2023· 4 citedOpen Access
Clinical Impact of Polymerase Chain Reaction–Based <i>Aspergillus</i> and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study
Clinical Infectious Diseases·2023· 52 citedOpen Access
Exposure of anti-infective drugs and the dynamic changes of the gut microbiota during gastrointestinal mucositis in autologous stem cell transplant patients: a pilot study
Annals of Hematology·2023· 3 citedOpen Access
Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial
International Journal of Antimicrobial Agents·2023· 23 citedOpen Access
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
Nature Medicine·2021· 135 citedOpen Access
Efficacité et sécurité de l’avapritinib (AVA) chez les patients atteints de mastocytose avancée (AdvSM) : résultats intermédiaires de l’étude PATHFINDER de phase 2
Annales de Dermatologie et de Vénéréologie - FMC·2021
Abstract CT023: PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM)
Cancer Research·2021· 2 cited
Ganciclovir therapeutic drug monitoring in transplant recipients
Journal of Antimicrobial Chemotherapy·2021· 51 citedOpen Access
The Added Value of [18F]FDG PET/CT in the Management of Invasive Fungal Infections
Diagnostics·2021· 23 citedOpen Access
Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
The Journal of Allergy and Clinical Immunology In Practice·2020· 29 citedOpen Access
Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review
BMJ Open·2020· 2 citedOpen Access
1538. Who Will Benefit From Therapeutic Drug Monitoring of Ganciclovir?
Open Forum Infectious Diseases·2019Open Access
Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature
Clinical Lymphoma Myeloma & Leukemia·2019Open Access
page 1 of 4Next →

Frequent Co-authors

Jan‐Willem C. Alffenaar(14), Tjip S. van der Werf(11), Edwin R. van den Heuvel(8), Jos G. W. Kosterink(8), Anette Veringa(7), Jason Gotlib(5), Jens Panse(5), Olivier Hermine(5), Bart Rijnders(5), Donald R. A. Uges(5), Martijn Bakker(4), Daan J. Touw(4), Marjolijn J. P. van Wanrooy(4), S. Alvi(4), Erwin Robin(4), D. Alston(4), Hanneke C. Kluin‐Nelemans(4), Kim C. M. van der Elst(3), Jan G. Zijlstra(3), Andreas Reiter(3)